LFMDHealthcare · Health Information ServicesThe 8 Wall Street analysts covering LifeMD, Inc. hold a median 12-month price target of $7.5 — +206.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 4 Nov 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores LifeMD, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (83): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (8): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on LFMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +206.1% from it.
Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $9.00 |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $10 → $9.00 |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Aug 2026 | B. Riley Securities | Maintains | Buy | — |
| 6 Aug 2026 | B. Riley Securities | Maintains | Buy | $10 → $8.00 |
| 6 Aug 2026 | BTIG | Maintains | Buy | $10 → $9.00 |
| 6 Aug 2026 | BTIG | Maintains | Buy | — |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 May 2026 | BTIG | Reiterates | Buy | — |
| 16 Mar 2026 | Mizuho | Upgrade | Outperform | — |
| 12 Mar 2026 | Freedom Broker | Maintains | Buy | — |
| 12 Mar 2026 | Freedom Capital Markets | Maintains | Buy | $8.00 → $10 |
| 11 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Mar 2026 | BTIG | Reiterates | Buy | — |
| 24 Nov 2025 | Freedom Broker | Maintains | Buy | — |
| 19 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Nov 2025 | Keybanc | Maintains | Overweight | — |
| 19 Nov 2025 | Mizuho | Maintains | Neutral | — |
| 18 Nov 2025 | B. Riley Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LFMD appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, LifeMD, Inc. returned −54.8% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 60% of US stocks
Cheaper than 80% of US stocks
Cheaper than 7% of US stocks
Cheaper than 80% of US stocks
Higher than 22% of US stocks
Higher than 19% of US stocks
Higher than 96% of US stocks
Higher than 23% of US stocks
Higher than 47% of US stocks
Higher than 3% of US stocks
Higher than 20% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
LifeMD, Inc. has a market value of $105.2M and an enterprise value of $86.0M.
Revenue in the twelve months to 30 June 2026: $164.7M. The latest quarter shrank 3.5% year on year.
Net income over the same four quarters: $430K, a 0.3% net margin.
Diluted earnings per share, trailing twelve months: $−0.05.
Free cash flow in the twelve months to 30 June 2026: −$18.3M, after $7.2M of capital spending.
LifeMD, Inc. spent $3.1M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 8.7×; forward P/E: 5.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
LifeMD, Inc. employs 347 people — $475K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own LifeMD, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
LifeMD said it will report financial results for the three and nine months ended September 30, 2026, before U.S. markets open on November 9. The company will host a conference call at 8:30 a.m. Eastern that day.
Why it matters — LFMD watchers can note the scheduled date and time for the company’s upcoming results and conference call.
LifeMD, Inc. announced that its Board of Directors authorized a cash dividend on its 8.875% Series A Cumulative Perpetual Preferred Stock, equal to $0.5546875 per share, payable to holders of the stock.
Why it matters — LFMD watchers would care because the news confirms the company is continuing to make scheduled dividend payments to its preferred shareholders.
AT&T has teamed up with LifeMD to offer complimentary LifeMD memberships to AT&T customers, providing access to virtual care, prescriptions, and pharmacy services. The partnership expands AT&T's customer benefits through LifeMD's telehealth offerings.
Why it matters — A partnership with a major telecom such as AT&T could broaden LifeMD's exposure to a large customer base, potentially increasing adoption of its virtual care services.
LifeMD reported disappointing Q2 2026 results, lowering its revenue and EBITDA guidance and posting a sequential subscriber decline. The company is shifting from auction-based marketing to partnerships with manufacturers, employers, and insurers to reduce customer acquisition costs, which currently stand at 59% of revenue.
Why it matters — LFMD watchers would care because high customer acquisition costs are pressuring EBITDA, and management's strategic shift toward partnerships could determine whether the profitable core model (88% gross margin) translates into sustained earnings.
AT&T has announced an exclusive collaboration with LifeMD, becoming the first and only carrier to offer eligible wireless and fiber customers free access to a LifeMD membership, a $228 annual value, with on-demand access to the company's nationwide virtual care and pharmacy platform.
Why it matters — This exclusive partnership broadens LifeMD's distribution reach and exposure to a large carrier customer base, potentially expanding its user adoption.
The 8 Wall Street analysts covering LifeMD, Inc. have a median 12-month price target of $7.5, with estimates ranging from $5 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering LifeMD, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LifeMD, Inc. 45 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, LifeMD, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (83 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +206.1% from the last close, and Ticker Nerd's factor model ranks LifeMD, Inc. 45 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering LifeMD, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LFMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $15 over the next 12 months.
LifeMD, Inc. returned -54.8% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
LifeMD, Inc. is a direct-to-patient telehealth company that provides virtual medical care and pharmacy services across the United States.
The most recent item we track (GlobeNewsWire, 20 Oct 2026): "LifeMD to Report Third Quarter 2026 Financial Results on November 9". LifeMD said it will report financial results for the three and nine months ended September 30, 2026, before U.S. markets open on November 9. The company will host a conference call at 8:30 a.m. Eastern that day.
LifeMD, Inc. is a direct-to-patient telehealth company that provides virtual medical care and pharmacy services across the United States. LifeMD’s platform connects patients with licensed healthcare providers for primary care, urgent care, and chronic care management, supported by digital prescribing, lab testing, and care coordination tools. The company also offers specialized consumer health brands focused on men’s health, hair loss, women’s health, allergy and asthma care, and other common conditions, along with related prescription and over-the-counter products. In addition, LifeMD serves patients through subscription and membership-based care models designed to make access to healthcare more convenient and streamlined. Headquartered in New York, LifeMD operates at the intersection of telehealth, pharmacy fulfillment, and digital healthcare services.
CEO Mr. Justin Schreiber · 347 employees · United States · https://lifemd.com
